Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM) (MARINA)

27. April 2026 aktualisiert von: iOMEDICO AG

Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable. Over the course of the disease, patients eventually become refractory to the various treatments. Therefore, new therapeutic options which utilize new mechanisms of action are essential.

Melphalan flufenamide (melflufen) represents such an additional therapeutic approach. Melflufen is a peptide-drug conjugate (PDC) which is highly lipophilic and rapidly incorporated into the tumor cells. Once inside the tumor cell, melflufen is hydrolyzed by peptidases, including aminopeptidases and esterases, to release its alkylator payload. The alkylating agent then induces DNA damage resulting in cell death.

Melphalan flufenamid in combination with Dexamethason was approved by the European Medicines Agency (EMA) in August 2022 for the treatment of patients with triple class refractory relapsed/refractory Multiple Myeloma who have received at least 3 prior lines of therapy. For patients with prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.

The non-interventional study MARINA aims to address open scientific questions regarding the effectiveness, as well as therapy and safety management of melflufen in a real-world setting. By collecting comprehensive real-world data - including the Disease Control Rate (DCR) as a key endpoint, which is of most value for patients in this late disease stage - MARINA will investigate the therapeutic benefit of melflufen in routine clinical practice.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

50

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

  • Name: Sina Grebhardt, PhD
  • Telefonnummer: +49 761 / 15 242-0
  • E-Mail: info@iomedico.com

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Nicht-Wahrscheinlichkeitsprobe

Studienpopulation

Adult patients (≥18 years old) with relapsed and/or refractory multiple myeloma (R/RMM) pretreated with a proteasome inhibitor, an immunomodulatory drug and a CD38 antibody with decision for treatment with melflufen (Pepaxti®) and dexamethasone in fourth or later line according to SmPC.

Beschreibung

Inclusion Criteria:

  • Patients with R/RMM who have previously been treated with at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who relapsed on or after the last therapy
  • Indication and decision for fourth- or later-line treatment with melflufen (Pepaxti®) and dexamethasone, according to current SmPC as assessed by the treating physician
  • Signed and dated written informed consent*.
  • Treatment decision before inclusion into this non-interventional study

  • Age ≥18 years

    • Patients are allowed to be enrolled up to 28 days (+ 14 days) after their first dose of melflufen+dexamethasone,, but before any response assessment and second dose of melflufen+dexamethasone. These patients will not participate in the PRO assessments.

Exclusion Criteria:

  • Participation in an interventional clinical trial (except follow-up)
  • Patient unable to consent
  • Contraindications according to current SmPC

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Disease control rate (DCR)
Zeitfenster: max. 38 months (FPI - LPLV)
DCR is defined as the proportion of patients achieving a remission (i.e., sCR, CR, VGPR or PR or MR) or stable disease as best response according to local medical standards during treatment with melflufen. Patients without response measurement are considered non-responders.
max. 38 months (FPI - LPLV)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Progression-free survival (PFS)
Zeitfenster: max. 38 months (FPI - LPLV)
PFS is defined as the time from start of melflufen treatment until first progression or death from any cause, whichever comes first. Patients without disease progression or death at the time of analysis will be censored at their date of last contact. PFS will be calculated using the Kaplan-Meier method.
max. 38 months (FPI - LPLV)
Overall survival (OS)
Zeitfenster: max. 38 months (FPI - LPLV)
OS is defined as the time from start of melflufen treatment until death from any cause. Patients without documented death will be censored with their date of last contact. OS will be calculated using the Kaplan-Meier method.
max. 38 months (FPI - LPLV)
Overall response rate (ORR)
Zeitfenster: max. 38 months (FPI - LPLV)
ORR is defined as the proportion of patients achieving a remission (sCR, CR, VGPR or PR or MR) as best response according to local medical standards. Patients without response measurement are considered non-responders.
max. 38 months (FPI - LPLV)
Duration of treatment with melflufen
Zeitfenster: max. 38 months (FPI - LPLV)
Duration of melflufen treatment will be calculated in weeks as the time from first application to the last documented application of melflufen.
max. 38 months (FPI - LPLV)
Clinical benefit rate (CBR)
Zeitfenster: max. 38 months (FPI - LPLV)
CBR is defined as the proportion of patients achieving a sCR, CR, VGPR, PR or MR as best response according to local medical standards during treatment with melflufen. Patients without response measurement are considered non-responders.
max. 38 months (FPI - LPLV)
Time to next treatment (TTNT)
Zeitfenster: max. 38 months (FPI - LPLV)
TTNT is defined as the time from start of melflufen treatment until start of the following therapy line or death, whichever comes first. Patients alive and without subsequent treatment at the time of analysis will be censored at their date of last contact. TTNT will be calculated using the Kaplan-Meier method.
max. 38 months (FPI - LPLV)
PFS2
Zeitfenster: max. 38 months (FPI - LPLV)
PFS2 is defined as the time from start of melflufen treatment until progression or death during first subsequent treatment line, whichever comes first. If subsequent line is not reached, previous-line death will serve as event. Patients without progression after the start of the subsequent line or death at the time of analysis will be censored at their date of last contact. PFS2 will be calculated using the Kaplan-Meier method.
max. 38 months (FPI - LPLV)
PFS of first subsequent treatment line
Zeitfenster: max. 38 months (FPI - LPLV)
PFS of first subsequent treatment line is defined as time from start of first subsequent treatment line until first progression thereafter, or death from any cause, whatever comes first. Patients without progression or death at the time of analysis will be censored with their date of last contact. PFS of first subsequent treatment line will be calculated using the Kaplan-Meier method.
max. 38 months (FPI - LPLV)
(Serious) adverse events ((S)AE)
Zeitfenster: max. 38 months (FPI - LPLV)
The case- and patient-based incidence of (S)AEs will be provided.
max. 38 months (FPI - LPLV)
(Serious) adverse drug reactions ((S)ADR) related to melphalan flufenamid
Zeitfenster: max. 38 months (FPI - LPLV)
The case- and patient-based incidence of (S)ADRs will be provided.
max. 38 months (FPI - LPLV)
Types of treatments prior to Melflufen
Zeitfenster: max. 38 months (FPI - LPLV)
To illustrate the prior treatments, the substances administered before Melflufen are listed by treatment line.
max. 38 months (FPI - LPLV)
Melfalan flufenamid starting dose
Zeitfenster: max. 38 months (FPI - LPLV)
Frequencies of patients with specific melflufen starting dose (i.e., 40mg, 30mg, other) will be provided.
max. 38 months (FPI - LPLV)
Absolute dose intensity of melphalan flufenamid
Zeitfenster: max. 38 months (FPI - LPLV)
Absolute dose intensity of melphalan flufenamid will be displayed with descriptive statistics.
max. 38 months (FPI - LPLV)
Relative dose intensity of melphalan flufenamid
Zeitfenster: max. 38 months (FPI - LPLV)
Relative dose intensity of melphalan flufenamid will be displayed with descriptive statistics.
max. 38 months (FPI - LPLV)
Type of dose modifications
Zeitfenster: max. 38 months (FPI - LPLV)
Type of dose modifications will be displayed with descriptive statistics.
max. 38 months (FPI - LPLV)
Frequency of dose modifications
Zeitfenster: max. 38 months (FPI - LPLV)
Frequency of dose modifications will be displayed with descriptive statistics.
max. 38 months (FPI - LPLV)
Reasons for dose modifications
Zeitfenster: max. 38 months (FPI - LPLV)
Reasons for dose modifications will be displayed with descriptive statistics.
max. 38 months (FPI - LPLV)
Substances of subsequent antineoplastic treatment
Zeitfenster: max. 38 months (FPI - LPLV)
Frequencies of substances used will be displayed in a summary table.
max. 38 months (FPI - LPLV)
Global health-related quality of life during course of treatment
Zeitfenster: max. 38 months (FPI - LPLV)
The change from baseline (i.e., difference) in the scales of the EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer quality of life questionnaire C30) will be displayed for each point in time, using boxplots.
max. 38 months (FPI - LPLV)
Multiple myeloma related quality of life during course of treatment
Zeitfenster: max. 38 months (FPI - LPLV)
The change from baseline (i.e., difference) in the scales of the EORTC QLQ-MY20 (European Organisation for Research and Treatment of Cancer quality of life questionnaire MY20) will be displayed for each point in time, using boxplots.
max. 38 months (FPI - LPLV)
Assessing parameters of physician treatment decision making
Zeitfenster: max. 38 months (FPI - LPLV)
Results of therapy decision questionnaires will be displayed with frequencies in a summary table.
max. 38 months (FPI - LPLV)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

iOMEDICO AG

Mitarbeiter

Oncopeptides AB

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

15. Mai 2026

Primärer Abschluss (Geschätzt)

30. Juni 2029

Studienabschluss (Geschätzt)

30. Juni 2029

Studienanmeldedaten

Zuerst eingereicht

20. April 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

27. April 2026

Zuerst gepostet (Tatsächlich)

30. April 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. April 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

27. April 2026

Zuletzt verifiziert

1. April 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • IOM-120481

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Multiples Myelom

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in Belgium

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren